Revenue: As of FY2025, the actual value is USD 52.15 M, beating the estimate of USD 49.42 M.EPS: As of FY2025, the actual value is USD 1.46.EBIT: As of FY2025, the actual value is USD 44.85 M.<h4>Portfolio Receipts</h4><ul><li>Total Portfolio Receipts (FY2025): XOMA Royalty Corporation reported total portfolio receipts of over $50 million for fiscal year 2025.</li><li>Royalty Receipts (FY2025): Royalty receipts for FY2025 were $33.6 million, an increase of 68% compared to the previous period.<ul><li>Four programs each contributed over $1.5 million in royalty receipts, with two approved within the last two years.</li></ul></li><li>Milestone Receipts (FY2025): Milestone receipts for FY2025 totaled $16.9 million, contributed by six programs.</li><li>Royalty Receipts Trend:<ul><li>FY 2023: $9.0 million</li><li>FY 2024: $16.9 million</li><li>FY 2025: $33.6 million</li></ul></li><li>Milestone Receipts Trend:<ul><li>FY 2023: $6.6 million</li><li>FY 2024: $20.0 million</li><li>FY 2025: $16.9 million</li></ul></li><li>Total Milestone Receipts (since 2017): The company has accumulated over $140 million in total milestone receipts since 2017.</li><li>Future Potential Milestones: Future potential milestones are estimated to be over $3 billion.</li></ul><h4>Cash Flow</h4><ul><li>Positive Cash Flow from Operations (FY2025): XOMA Royalty Corporation achieved positive cash flow from operations in FY2025.</li></ul><h4>Capital and Investments</h4><ul><li>Non-Dilutive Capital: Approximately $12 million in non-dilutive capital was acquired since January 2025.</li><li>Beginning Cash (FY2025): The company started FY2025 with approximately $83 million in cash, which represents 45% more cash compared to FY2023.</li><li>Cash and Cash Equivalents (YE25): Cash and cash equivalents at year-end 2025 stood at $83 million.</li></ul><h4>Shareholder Returns</h4><ul><li>Share Repurchase (FY2025): In FY2025, XOMA Royalty Corporation repurchased $16 million worth of shares, retiring approximately 648,000 shares at an average price of $24.75.</li></ul><h4>Portfolio Growth (2023 vs. Today)</h4><ul><li>Commercial Assets: Commercial assets increased from 1 to 7, a 7x growth.</li><li>Late Stage (Phase 3 / Registrational) Assets: Late-stage assets grew from 2 to 14.</li><li>Phase 2 &amp; Earlier Assets: Phase 2 and earlier assets increased from 57 to over 100.</li><li>Total Assets: The total number of assets grew from approximately 60 to over 120, representing a 2x growth.</li></ul><h4>Current Capitalization (as of 3/16/2026)</h4><ul><li>Share Price: The share price was $26.61 per share.</li><li>Shares (Fully Diluted): Fully diluted shares amounted to 17.6 million.</li><li>Market Cap (Fully Diluted): The fully diluted market capitalization was approximately $469 million.</li><li>Perpetual Preferreds: Perpetual preferreds were approximately $568 million.</li><li>Enterprise Value: The enterprise value was $69 million.</li><li>Royalty Backed Loan: A royalty-backed loan of $113 million was reported.</li></ul><h4>Outlook / Guidance</h4>XOMA Royalty Corporation anticipates future potential monetization opportunities and significant financial contributions from collaborations. The company forecasts continued revenue and cash flow growth, driven by an increasing number of royalties and low expenses. Key portfolio events anticipated in 2026 include regulatory decisions, data announcements for various drug candidates, and product launches.

XOMA Royalty | 8-K: FY2025 Revenue Beats Estimate at USD 52.15 M